Abstract:One of the major obstacles in human epidermal growth factor receptor 2 (HER2)-specific trastuzumab antibody immunotherapy of HER2-positive breast cancer is the development of trastuzumab resistance, warranting the search for other therapeutic strategies. Using mouse models, we previously demonstrated that ovalbumin (OVA)-specific dendritic cell (DC)-released exosome (EXOOVA)-targeted CD4+ T cell-based (OVA-TEXO) vaccine stimulates efficient cytotoxic T lymphocyte (CTL) responses via exosomal peptide/major histocompatibility complex (pMHC)-I, exosomal CD80 and endogenous IL-2 signaling; and long-term CTL memory by means of via endogenous CD40L signaling. In this study, using two-photon microscopy, we provide the first visual evidence on targeting OVA-TEXO to cognate CD8+ T cells in vivo via exosomal pMHC-I complex. We prepared HER2/neu-specific Neu-TEXO and HER2-TEXO vaccines using adenoviral vector (AdVneu and AdVHER2)-transfected DC (DCneu and DCHER2)-released EXOs (EXOneu and EXOHER2), and assessed their stimulatory effects on HER2/neu-specific CTL responses and antitumor immunity. We demonstrate that Neu-TEXO vaccine is capable of stimulating efficient neu-specific CTL responses, leading to protective immunity against neu-expressing Tg1-1 breast cancer in all 6/6 transgenic (Tg) FVBneuN mice with neu-specific self-immune tolerance. We also demonstrate that HER2-TEXO vaccine is capable of inducing HER2-specific CTL responses and protective immunity against transgene HLA-A2+HER2+ BL6-10A2/HER2 B16 melanoma in 2/8 double Tg HLA-A2/HER2 mice with HER2-specific self-immune tolerance. The remaining 6/8 mice had significantly prolonged survival. Furthermore, we demonstrate that HER2-TEXO vaccine stimulates responses of CD8+ T cells capable of not only inducing killing activity to HLA-A2+HER2+ BL6-10A2/HER2 melanoma and trastuzumab-resistant BT474A2 breast cancer cells in vitro but also eradicating 6-day palpable HER2+ BT474A2 breast cancer (3–4 mm in diameter) in athymic nude mice. Therefore, the novel T cell-based HER2-TEXO vaccine may provide a new therapeutic alternative for women with HER2+ breast cancer, especially for trastuzumab-resistant HER2+ breast cancer patients.

Immunocontraception of a Gene Vaccine Based on the Extracellular Domain of HER--2/neu

Application of a Gene Vaccine Targeting HER-2/neu in Immunocontraception.

The regulation on the immune responses against proto-oncogene HER-2/neu following DNA vaccination by C3d molecule

[Specifics Anti-Tumor Immunity Induced by Gene Immunization with Ectopic Hcgbeta Encoding Gene].

The Study of Immunological Response to Long-Term Releaes System of Hcd Microsphere System in C_(57) Black Mouse

Antifertility effect in mice after vaccination with plasmid DNA encoding mouse sperm equatorial segment protein

HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination

Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor.

[Construction of the DNA Vaccine of Major Outer Membrane Protein of Neisseria Gonorrhoeae and Investigation of Immune Effects after Vaccination].

C3d3 Enhances Anti-Hcgβ Response by Gene Fusion to Hcgβ in DNA Immunization in Mice of Different Strains

IMMUNOGENE THERAPY OF TUMORS WITH A VACCINE BASED ON THE LIGAND-BINDING DOMAIN OF CHICKEN HOMOLOGOUS INTEGRINβ3

Targeted Delivery of Tumor Antigens to Activated Dendritic Cells Via CD11c Molecules Induces Potent Antitumor Immunity in Mice

HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model

A DNA vaccine (EG95-PT1/2/3-IL2) encoding multi-epitope antigen and IL-2 provokes efficient and long-term immunity to echinococcosis

The Construction of PCV2 DNA Vaccine and Its Immune Response in Mouse

Fusion of hC3d3 to hCGβ enhances responsiveness in vitro of human peripheral immunocompetent cells upon the antigen primary challenge

Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion

Prevention of nodules and enhancement of antibody response to genetically engineered recombinant vaccine against Human Chorionic Gonadotropin (hCG) for contraception

Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-gamma-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector.

Exosomal Pmhc-I Complex Targets T Cell-Based Vaccine to Directly Stimulate CTL Responses Leading to Antitumor Immunity in Transgenic FVBneuN and HLA-A2/HER2 Mice and Eradicating Trastuzumab-Resistant Tumor in Athymic Nude Mice

Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity